TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ascentage Pharma Group International Unsponsored ADR ( (AAPG) ) has issued an update.
On November 24, 2025, Ascentage Pharma announced the publication of promising Phase Ib clinical trial results for olverembatinib in treating succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST), a rare and challenging cancer subtype. The study, published in the prestigious journal Signal Transduction and Targeted Therapy, showed that olverembatinib demonstrated significant efficacy and safety, with a clinical benefit rate of 84.6% and a median progression-free survival of 25.7 months. This advancement highlights a novel mechanism of action involving lipid metabolism modulation, offering a potential new treatment avenue for SDH-deficient GIST, which currently lacks effective therapies.
The most recent analyst rating on (AAPG) stock is a Sell with a $33.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International Unsponsored ADR stock, see the AAPG Stock Forecast page.
Spark’s Take on AAPG Stock
According to Spark, TipRanks’ AI Analyst, AAPG is a Underperform.
The overall stock score reflects significant financial challenges, including high debt levels and negative profitability, which are the most impactful factors. The technical analysis indicates weak momentum, and the valuation is unattractive due to negative earnings and lack of dividends. These factors collectively result in a low overall score.
To see Spark’s full report on AAPG stock, click here.
More about Ascentage Pharma Group International Unsponsored ADR
Ascentage Pharma Group International is a global, commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies to address unmet medical needs in cancer. The company has developed a robust pipeline of innovative drug products, including inhibitors targeting key proteins in the apoptotic pathway and next-generation kinase inhibitors. Its lead product, olverembatinib, is a third-generation BCR-ABL1 inhibitor approved in China for treating chronic myeloid leukemia (CML) and is being evaluated for other indications, including gastrointestinal stromal tumors (GIST).
Average Trading Volume: 8,205
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.95B
For detailed information about AAPG stock, go to TipRanks’ Stock Analysis page.